GC Pharma pledges free Covid-19 treatment, if it's approved
Published: 18 May. 2020, 17:33
The Yongin, Gyeonggi-based pharmaceutical company's treatment candidate, called GC5131A, is a hyperimmune globulin that is made with immune proteins collected from recovered Covid-19 patients.
GC is the first Korean drugmaker to make such a pledge about a potential Covid-19 treatment.
The decision, the company said, is intended to contribute to public health efforts to rein in the coronavirus pandemic, adding that it won’t place any cap on the quantity of the treatments to be circulated.
The pharmaceutical unit is hoping for commercialization the drug by the second half of 2020.
BY PARK EUN-JEE [[email protected]]
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)